Listen

Press releases

Receive e-mail alerts

Interne link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
april 13, 2022 om 11:00 AM UTC
Interne link ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
april 04, 2022 om 11:00 AM UTC
Interne link ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit
maart 23, 2022 om 08:30 PM UTC
Interne link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
maart 07, 2022 om 12:00 PM UTC
Interne link ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
februari 24, 2022 om 12:00 PM UTC
Interne link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
februari 11, 2022 om 12:00 PM UTC
Interne link ProQR to Present at Upcoming SVB Leerink Conference
februari 07, 2022 om 09:30 PM UTC
Interne link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
januari 04, 2022 om 12:00 PM UTC
Interne link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
december 30, 2021 om 12:00 PM UTC
Interne link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
december 16, 2021 om 12:00 PM UTC
Interne link ProQR Announces Highlights from Analyst Event
november 18, 2021 om 09:01 PM UTC
Interne link ProQR to Webcast Virtual Analyst Event on November 18
november 11, 2021 om 12:00 PM UTC
Interne link ProQR Announces Upcoming Investor Conferences in November and December
november 08, 2021 om 09:30 PM UTC
Interne link ProQR Announces Third Quarter 2021 Operating and Financial Results
november 04, 2021 om 11:00 AM UTC
Interne link ProQR Appoints Theresa Heggie as Chief Commercial Officer
oktober 04, 2021 om 12:00 PM UTC
Interne link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
september 08, 2021 om 08:15 PM UTC
Interne link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
september 08, 2021 om 08:01 PM UTC
Interne link ProQR Announces Virtual Presentation at EURETINA 2021
september 06, 2021 om 08:15 PM UTC
Interne link ProQR Announces Upcoming Investor Conferences
september 03, 2021 om 12:00 PM UTC
Interne link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
augustus 11, 2021 om 08:30 PM UTC
Interne link ProQR Announces Second Quarter 2021 Operating and Financial Results
augustus 05, 2021 om 11:00 AM UTC
Interne link ProQR to Present at Upcoming JMP Securities Life Sciences Conference
juni 10, 2021 om 11:00 AM UTC
Interne link ProQR Announces First Quarter 2021 Operating and Financial Results
mei 06, 2021 om 11:00 AM UTC
Interne link ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
mei 04, 2021 om 11:00 AM UTC
Interne link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
april 23, 2021 om 11:00 AM UTC

Press releases

Interne link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Interne link ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

Interne link ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

Interne link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

Interne link ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Interne link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

Interne link ProQR to Present at Upcoming SVB Leerink Conference

Interne link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

Interne link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

Interne link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

Interne link ProQR Announces Highlights from Analyst Event

Interne link ProQR to Webcast Virtual Analyst Event on November 18

Interne link ProQR Announces Upcoming Investor Conferences in November and December

Interne link ProQR Announces Third Quarter 2021 Operating and Financial Results

Interne link ProQR Appoints Theresa Heggie as Chief Commercial Officer

Interne link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform

Interne link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

Interne link ProQR Announces Virtual Presentation at EURETINA 2021

Interne link ProQR Announces Upcoming Investor Conferences

Interne link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference

Interne link ProQR Announces Second Quarter 2021 Operating and Financial Results

Interne link ProQR to Present at Upcoming JMP Securities Life Sciences Conference

Interne link ProQR Announces First Quarter 2021 Operating and Financial Results

Interne link ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

Interne link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021